Predictive marker for response to trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer patients

Predictive marker for response to trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer patients

Abstract Objective Trifluridine/tipiracil (FTD/TPI) is one of the options for late-line treatment of colorectal cancer (CRC). However, the specific patient populations that would particularly benefit from it remain unclear. This study attempted to identify predictive markers of chemotherapy efficacy...

Full description

Saved in:
Bibliographic Details
Main Authors: Toshiaki Takahashi, Kunitoshi Shigeyasu, Yoshitaka Kondo, Sho Takeda, Hibiki Umeda, Kazuya Moriwake, Masashi Kayano, Yuya Sakurai, Shunsuke Nakamura, Masafumi Takahashi, Kaori Nitta, Kazuhiro Yoshida, Yuki Matsumi, Hiroyuki Michiue, Hideki Yamamoto, Hiroyuki Kishimoto, Fuminori Teraishi, Ryohei Shoji, Nobuhiko Kanaya, Hajime Kashima, Yoshihiko Kakiuchi, Shinji Kuroda, Shunsuke Kagawa, Toshiyoshi Fujiwara
Format: Article
Language:English
Published: BMC 2025-01-01
Series:BMC Cancer
Subjects:
ADAR1
Colorectal cancer
Biomarker
Trifluridine/tipiracil
Online Access:https://doi.org/10.1186/s12885-024-13370-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-024-13370-8

Similar Items